Table 2.

Toxicities experienced by the 27 patients on study deemed to be possibly, probably, or definitely related to bortezomib therapy

ToxicityGrade 2 (%)Grade 3 (%)Grade 4 (%)
Anorexia0/27 (0)1/27 (3.7)0/27 (0)
Bone pain1/27 (3.7)0/27 (0)0/27 (0)
Constipation5/27 (18.52)0/27 (0)0/27 (0)
Cough1/27 (3.7)0/27 (0)0/27 (0)
Diarrhea2/27 (7.41)1/27 (3.7)0/27 (0)
Dizziness0/27 (0)3/27 (11.11)0/27 (0)
Dysgeusia1/27 (3.7)0/27 (0)0/27 (0)
Dyspnea1/27 (3.7)0/27 (0)0/27 (0)
Edema1/27 (3.7)0/27 (0)0/27 (0)
Fatigue9/27 (33.33)1/27 (3.7)0/27 (0)
Headache1/27 (3.7)0/27 (0)0/27 (0)
Hypotension1/27 (3.7)1/27 (3.7)0/27 (0)
Infection3/27 (11.11)1/27 (3.7)0/27 (0)
Insomnia1/27 (3.7)0/27 (0)0/27 (0)
Leukopenia6/27 (22.22)5/27 (18.52)0/27 (0)
Liver function abnormalities2/27 (7.41)0/27 (0)0/27 (0)
Mood alteration/depression1/27 (3.7)0/27 (0)0/27 (0)
Mucositis1/27 (3.7)0/27 (0)0/27 (0)
Myalgia1/27 (3.7)0/27 (0)0/27 (0)
Nausea4/27 (14.81)1/27 (3.7)0/27 (0)
Neutropenia3/27 (11.11)3/27 (11.11)1/27 (3.7)
Pleural effusion0/27 (0)1/27 (3.7)0/27 (0)
Rash4/27 (14.81)0/27 (0)0/27 (0)
Sensory neuropathy5/27 (22.22)6/27 (22.2)0/27 (0)
Thrombocytopenia4/27 (14.81)2/27 (7.41)0/27 (0)
Weakness2/27 (7.41)0/27 (0)0/27 (0)
Xerophthalmia1/27 (3.7)0/27 (0)0/27 (0)